Sangamo Therapeutics, Inc. (SGMO) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Sangamo Therapeutics, Inc. (SGMO) Bundle
Simplify Sangamo Therapeutics, Inc. (SGMO) valuation with this customizable DCF Calculator! Featuring real Sangamo Therapeutics, Inc. (SGMO) financials and adjustable forecast inputs, you can test scenarios and uncover Sangamo Therapeutics, Inc. (SGMO) fair value in minutes.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 102.4 | 118.2 | 110.7 | 111.3 | 176.2 | 206.2 | 241.2 | 282.1 | 330.1 | 386.1 |
| Revenue Growth, % | 0 | 15.39 | -6.34 | 0.54019 | 58.34 | 16.98 | 16.98 | 16.98 | 16.98 | 16.98 |
| EBITDA | -101.3 | -123.9 | -173.9 | -189.2 | -87.4 | -184.9 | -216.3 | -253.1 | -296.0 | -346.3 |
| EBITDA, % | -98.85 | -104.8 | -157.09 | -169.97 | -49.61 | -89.69 | -89.69 | -89.69 | -89.69 | -89.69 |
| Depreciation | 3.9 | 5.7 | 9.4 | 12.1 | 22.2 | 16.8 | 19.6 | 22.9 | 26.8 | 31.4 |
| Depreciation, % | 3.84 | 4.81 | 8.53 | 10.88 | 12.59 | 8.13 | 8.13 | 8.13 | 8.13 | 8.13 |
| EBIT | -105.2 | -129.6 | -183.3 | -201.3 | -109.6 | -190.6 | -222.9 | -260.8 | -305.1 | -356.9 |
| EBIT, % | -102.69 | -109.61 | -165.61 | -180.85 | -62.2 | -92.44 | -92.44 | -92.44 | -92.44 | -92.44 |
| Total Cash | 385.0 | 692.0 | 464.7 | 277.6 | 81.0 | 183.9 | 215.1 | 251.6 | 294.4 | 344.4 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 37.6 | 6.3 | 6.4 | 4.5 | 1.3 | 21.7 | 25.3 | 29.6 | 34.7 | 40.6 |
| Account Receivables, % | 36.7 | 5.3 | 5.75 | 4.02 | 0.75242 | 10.5 | 10.5 | 10.5 | 10.5 | 10.5 |
| Inventories | -22.5 | -50.5 | -88.2 | .0 | .0 | -59.5 | -69.6 | -81.5 | -95.3 | -111.5 |
| Inventories, % | -21.98 | -42.75 | -79.65 | 0.000000898 | 0 | -28.88 | -28.88 | -28.88 | -28.88 | -28.88 |
| Accounts Payable | 6.7 | 12.6 | 9.8 | 22.4 | 15.3 | 22.6 | 26.4 | 30.9 | 36.1 | 42.3 |
| Accounts Payable, % | 6.51 | 10.62 | 8.82 | 20.14 | 8.66 | 10.95 | 10.95 | 10.95 | 10.95 | 10.95 |
| Capital Expenditure | -20.7 | -14.7 | -23.3 | -20.2 | -21.2 | -34.5 | -40.4 | -47.3 | -55.3 | -64.7 |
| Capital Expenditure, % | -20.18 | -12.45 | -21.03 | -18.12 | -12 | -16.76 | -16.76 | -16.76 | -16.76 | -16.76 |
| Tax Rate, % | 1.93 | 1.93 | 1.93 | 1.93 | 1.93 | 1.93 | 1.93 | 1.93 | 1.93 | 1.93 |
| EBITAT | -83.6 | -129.9 | -183.7 | -201.7 | -107.5 | -182.0 | -212.9 | -249.1 | -291.4 | -340.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -108.7 | -73.7 | -162.7 | -283.4 | -110.5 | -153.3 | -223.5 | -261.4 | -305.8 | -357.8 |
| WACC, % | 9.15 | 9.23 | 9.23 | 9.23 | 9.22 | 9.21 | 9.21 | 9.21 | 9.21 | 9.21 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -973.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -365 | |||||||||
| Terminal Value | -5,062 | |||||||||
| Present Terminal Value | -3,258 | |||||||||
| Enterprise Value | -4,232 | |||||||||
| Net Debt | -7 | |||||||||
| Equity Value | -4,225 | |||||||||
| Diluted Shares Outstanding, MM | 174 | |||||||||
| Equity Value Per Share | -24.22 |
What You Will Get
- Real SGMO Financial Data: Pre-filled with Sangamo Therapeutics’ historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Sangamo’s intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive Historical Data: Sangamo’s (SGMO) past financial statements and pre-filled projections.
- Customizable Parameters: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Valuation: Observe Sangamo’s intrinsic value update instantly.
- Intuitive Visualizations: Dashboard graphs illustrate valuation outcomes and essential metrics.
- Designed for Precision: A robust tool tailored for analysts, investors, and finance professionals.
How It Works
- Download the Template: Gain immediate access to the Excel-based SGMO DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and additional parameters.
- Instant Calculations: The model automatically recalculates Sangamo Therapeutics' intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential valuation shifts.
- Analyze and Decide: Utilize the findings to inform your investment or financial analysis.
Why Choose This Calculator for Sangamo Therapeutics, Inc. (SGMO)?
- User-Friendly Interface: Tailored for users of all experience levels.
- Customizable Inputs: Adjust parameters easily to suit your financial analysis.
- Real-Time Valuation: Observe immediate updates to Sangamo’s valuation as you change inputs.
- Preloaded Data: Comes with Sangamo’s latest financial information for swift evaluations.
- Preferred by Experts: Utilized by analysts and investors for data-driven decisions.
Who Should Use This Product?
- Investors: Accurately assess Sangamo Therapeutics, Inc.'s (SGMO) fair value before making investment choices.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to Sangamo Therapeutics.
- Consultants: Easily modify the template for valuation reports tailored to clients in the biotech sector.
- Entrepreneurs: Discover insights into financial modeling practices employed by leading biotechnology firms.
- Educators: Implement it as a teaching resource to illustrate valuation methodologies in the life sciences industry.
What the Template Contains
- Historical Data: Includes Sangamo Therapeutics’ past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Sangamo Therapeutics’ intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Sangamo Therapeutics’ financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.